Drug Free Solution, Inc.
DSOL
$0.0002
$0.000.00%
| 02/28/2014 | 11/30/2013 | 08/31/2013 | 05/31/2013 | 02/28/2013 | |
|---|---|---|---|---|---|
| Revenue | 210.53% | 231.25% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 210.53% | 231.25% | -- | -- | -- |
| Cost of Revenue | 97.40% | 97.40% | 95.53% | 131.63% | -- |
| Gross Profit | -92.06% | -92.59% | -94.09% | -131.63% | -- |
| SG&A Expenses | 71.23% | -7.18% | -13.76% | 79.04% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.08% | 10.88% | 1.70% | 87.55% | -- |
| Operating Income | -81.91% | -10.37% | -1.58% | -87.51% | -- |
| Income Before Tax | -56.60% | -0.45% | 7.77% | -63.35% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.60% | -0.45% | 7.77% | -63.35% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.60% | -0.45% | 7.77% | -63.35% | -- |
| EBIT | -81.91% | -10.37% | -1.58% | -87.51% | -- |
| EBITDA | -81.27% | -137.54% | -136.45% | -1,266.81% | -- |
| EPS Basic | -5.38% | 36.31% | 40.13% | -16.38% | -- |
| Normalized Basic EPS | -26.53% | 29.21% | 33.71% | -31.25% | -- |
| EPS Diluted | -5.38% | 36.31% | 40.13% | -16.38% | -- |
| Normalized Diluted EPS | -26.53% | 29.21% | 33.71% | -31.25% | -- |
| Average Basic Shares Outstanding | 47.22% | 58.79% | 69.48% | 80.69% | -- |
| Average Diluted Shares Outstanding | 47.22% | 58.79% | 69.48% | 80.69% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
